Pfeiffer, Sebastian

[["dc.bibliographiccitation.journal","Ophthalmology Retina"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Klingelhöfer, Anthea"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Striebe, Nina-Antonia"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Koscielny, Juergen"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2021-06-01T10:49:52Z"],["dc.date.available","2021-06-01T10:49:52Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.oret.2021.04.013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86440"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","2468-6530"],["dc.title","Risk factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","aos.14940"],["dc.bibliographiccitation.firstpage","295"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","301"],["dc.bibliographiccitation.volume","100"],["dc.contributor.affiliation","Gebler, Marie; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Pfeiffer, Sebastian; 2\r\nDepartment of Research, Teaching and Clinical Science University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Callizo, Josep; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Hoerauf, Hans; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Feltgen, Nicolas; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.author","Gebler, Marie"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.date.accessioned","2021-07-05T14:57:41Z"],["dc.date.available","2021-07-05T14:57:41Z"],["dc.date.issued","2021"],["dc.date.updated","2022-06-14T21:23:28Z"],["dc.description.abstract","Abstract Purpose To assess the incidence of cystoid macular oedema (CME) diagnosed by spectral domain optical coherence tomography (SD‐OCT) after primary rhegmatogenous retinal detachment (RRD) surgery. Methods From April 2016 to October 2017, 150 eyes of 150 patients presenting with primary RRD were included consecutively in this prospective single‐centre study. Patients with the following characteristics were excluded: previous vitreoretinal surgery, combined cataract surgery, preoperatively presentation with any intraocular or systemic inflammatory condition, visible macular oedema or epiretinal membrane (ERM) on funduscopy. SD‐OCT (Spectralis, Heidelberg Engineering) was conducted 3 and 6 weeks after surgery. Results One hundred and twenty‐eight of the 150 patients completed the study, of whom 107 (age: 61.7 ± 11.5 years, mean ± SD) showed successful retinal attachment during follow‐up visits. The most frequent operation method was scleral buckling (54.2%), followed by vitrectomy (25.2%) and the combination of both techniques (20.6%). Postoperative SD‐OCT revealed CME, neurosensory detachment and ERM in 18.7, 31.8 and 32.7% of all cases, respectively. The risk of postoperative CME was significantly elevated in patients with ERM (42.9 versus 6.9%, p < 0.001). In addition, patients with initial detachment of the macula had more postoperative CME (26.5 versus 11.1%, p = 0.044). BCVA improvement was significantly lower in patients with CME compared to patients without 6 weeks after surgery for macula‐on RRD. Conclusions This prospective study confirmed that postoperative CME is a frequent complication after RRD surgery; we identified ERM and macula‐off RRD as potential risk factors. As CME potentially delays visual recovery, postoperative follow‐ups should include SD‐OCT."],["dc.identifier.doi","10.1111/aos.14940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87706"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-441"],["dc.relation.eissn","1755-3768"],["dc.relation.issn","1755-375X"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Incidence and risk factors for macular oedema after primary rhegmatogenous retinal detachment surgery: a prospective single‐centre study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0241005"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Gebest, Julia"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.editor","Grzybowski, Andrzej"],["dc.date.accessioned","2021-04-14T08:31:16Z"],["dc.date.available","2021-04-14T08:31:16Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0241005"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17683"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83535"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Influence of pars plana vitrectomy for macular surgery on the medium term intraocular pressure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","24096"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Berndzen, Lars"],["dc.contributor.author","Raber, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Paul, Christoph"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.date.accessioned","2022-01-11T14:08:03Z"],["dc.date.available","2022-01-11T14:08:03Z"],["dc.date.issued","2021"],["dc.description.abstract","The primary objective was to create and establish a new formula that predicts the individual probability of macular hole closure for eyes with full thickness macular holes (FTMH) accompanied by vitreomacular traction (VMT) which received enzymatic vitreolysis using intravitreally administered ocriplasmin. The secondary objective was to evaluate the forecast reliability of a previously published formula for VMT resolution in VMT-only eyes (Odds IVO-Success  = e Intercept  × OR years  × OR ln(µm) ; Probability IVO-Success  = Odds IVO-Success /(Odds IVO-Success  + 1)) on VMT resolution using the current dataset of eyes with FTMH accompanied by VMT. Retrospective analysis of the OASIS, ORBIT, and INJECT-studies. Patients with FTMH and VMT with complete information (n = 213) were included. The effect of gender, age, FTMH diameter, lens status and the presence of epiretinal membranes (ERM) on FTMH closure was assessed using separate univariate logistic regression analyses. With regard to VMT release separate univariate regression analyses were carried out and results were compared with formerly published data of VMT resolution in eyes with VMT only. Overall, 126 eyes (63%) experienced VMT resolution within 28 days. Younger age (p < 0.0001) and VMT diameter (p = 0.041) had a significant impact on VMT release. Overall, 81 eyes (38%) treated with ocriplasmin showed FTMH closure within 28 days. Univariate analysis of the different predictors analyzed revealed that FTMH diameter < 250 µm had a significant impact on treatment success (p = 0.0495). It was not possible to calculate and establish a new multivariate formula that can predict the individual FTMH closure probability for eyes with FTMHs and VMT. However, the results of VMT release prediction in eyes with FTMHs accompanied by VMT matched the prediction of VMT release in eyes with VMT only when using the previously published formula. All in all, predictors for calculating the individual probability of VMT resolution on the one hand and FTMH closure on the other hand are different suggesting diverse pathophysiological mechanisms."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1038/s41598-021-03509-z"],["dc.identifier.pii","3509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97924"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.relation.eissn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.title","Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","923"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Graefe s Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","934"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Bretag, Mirko"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Goldammer, Lena"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2018-11-07T10:24:17Z"],["dc.date.available","2018-11-07T10:24:17Z"],["dc.date.issued","2017"],["dc.description.abstract","Purpose To evaluate prospectively the efficacy and safety of a fixed bimonthly ranibizumab treatment regimen (RABIMO) in eyes with neovascular age-related macular degeneration (nAMD) and to compare these results with a pro re nata (PRN) treatment scheme. Methods This was a 12-month, phase IV, single center, randomised, non-inferiority study. Following three initial monthly injections, patients were randomised to receive either ranibizumab bimonthly (RABIMO group) or ranibizumab PRN (PRN group) (n = 20 each). Main outcome measures were best-corrected visual acuity (BCVA), central retinal thickness (CRT), number of injections, and adverse events (AEs). Results BCVA [median (interquartile range, IQR)] increased significantly in both groups after 12 months [RABIMO group +8.5 (14); PRN group +6.5 (16) ETDRS letters] when compared to baseline (p < 0.0001; p = 0.0085). At month 12, the RABIMO treatment regimen was non-inferior to the PRN scheme (Delta BCVA = 3.5 ETDRS letters; p < 0.0001). CRT was significantly reduced in both groups after the 12-month study period (p < 0.0001 each), with no significant difference between groups (p = 0.6772). Number of overall injections [median (IQR)] was 8 (0) in the RABIMO versus 4 (5) in the PRN group (p = 0.0037). Three patients in the RABIMO group received one additional unscheduled injection. We observed no significant differences between groups in the number of patients with reported SAEs/AEs (RABIMO group n = 6/15; PRN group n = 7/13) (p = 0.7357/p = 0.4902). Conclusions We found no evidence of significant functional or anatomical differences between the RABIMO and PRN treatment regimens. However, the RABIMO group's number of injections was twice as high as the PRN group's (protocol-driven). In light of potential side effects, the fixed bimonthly treatment regimen might not be advisable for routine clinical care, but it might be a worthwhile treatment option if monthly monitoring is not possible. Eudra-CT number: 2009-017324-11."],["dc.description.sponsorship","Novartis Pharma GmbH, Germany"],["dc.identifier.doi","10.1007/s00417-017-3589-x"],["dc.identifier.isi","000401436500008"],["dc.identifier.pmid","28102456"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42627"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1435-702X"],["dc.relation.issn","0721-832X"],["dc.title","Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0181766"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Ganser, Janina"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2019-07-09T11:43:38Z"],["dc.date.available","2019-07-09T11:43:38Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: Patients with retinal vascular occlusion disease have an increased risk for ischemic stroke and share some risk factors with cerebrovascular disease. The purpose of this study was to analyze the prevalence of atrial fibrillation (AF) in subjects with retinal vascular occlusive disease and anterior ischemic optic neuropathy and to compare these data to an ischemic stroke group. METHODS: Prospective, observational single-center trial. Subjects with retinal artery occlusion (RAO), retinal vein occlusion (RVO) and anterior ischemic optic neuropathy (AION) were included. Patients with ischemic stroke (IS) from a previous observational trial were used as control. Investigation included 7-day Holter ECG, echocardiography, duplex ultrasonography of the carotid arteries, and 24-hour blood pressure monitoring. Further vascular risk factors were documented. RESULTS: During the 1-year study period, 101 patients were recruited. The control group with ischemic stroke consisted of 272 subjects. At inclusion, the prevalence of AF was 12% (RAO), 10.2% (RVO), 11.1% (NAION) and 15.8% (IS). The final prevalence after Holter ECG rose to 16% (RAO), 18.4% (RVO), 14.8% (NAION) and 26.5% (IS). No significant difference was measured between groups. CONCLUSIONS: We detected a similar prevalence of AF in all groups. RVO patients tended to exhibit a higher AF detection rate and lower number needed to screen than RAO and NAION. The detection of AF rose considerably via Holter ECG. As a consequence, we recommend prolonged ECG monitoring in patients with acute ophthalmic vascular diseases."],["dc.identifier.doi","10.1371/journal.pone.0181766"],["dc.identifier.pmid","28771491"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14599"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58930"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","961"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","969"],["dc.bibliographiccitation.volume","258"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Striebe, Nina Antonia"],["dc.contributor.author","Khattab, Mohammed Haitham"],["dc.contributor.author","Affeldt, Johannes"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2020-12-10T14:10:35Z"],["dc.date.available","2020-12-10T14:10:35Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00417-019-04554-1"],["dc.identifier.eissn","1435-702X"],["dc.identifier.issn","0721-832X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70806"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Risk of perioperative bleeding complications in rhegmatogenous retinal detachment surgery: a retrospective single-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1559"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","1564"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Lahme, Eva"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Khattab, Mohammed"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Kulanga, Miroslav"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2018-10-08T09:22:04Z"],["dc.date.available","2018-10-08T09:22:04Z"],["dc.date.issued","2017-08"],["dc.description.abstract","To identify factors that may lead to a rapid progression in macula-on rhegmatogenous retinal detachment (RRD), in particular, those that may lead to macular involvement.Observational, prospective, single-center study. Patients referred for surgery due to primary rhegmatogenous retinal detachment with the macula on between 2009 and 2013 were included. Relevant factors analyzed included age, time delay until surgery, lens status, myopia, the detachment’s location and configuration as well as number, size and type of retinal breaks. Eyes underwent optical coherence tomography to detect macular detachment. A multivariate analysis was performed to investigate the effect of several factors in the progression of retinal detachment. A total of 116 eyes of 116 patients were included. Mean time delay between admission and surgery was 1.8 ± 1.4 days. Progression was observed in 19.8% of the eyes. Of those, 47.8% presented macular detachment. Ten of the 11 (90.9%) eyes presenting progression involving the macula also exhibited a bullous configuration, which was the only parameter that correlated significantly with detachment progression in patients with (p = 0.0036) and without (p = 0.0014) macular involvement. For the first time in a prospective trial, a bullous configuration was found to be a highly significant predictor for progression in macula-on detachments. Our data support prompt surgery in patients diagnosed with bullous macula-on RRD."],["dc.fs.pkfprnr","5911"],["dc.identifier.doi","10.1007/s00417-017-3696-8"],["dc.identifier.fs","627411"],["dc.identifier.pmid","28551879"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15876"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1435-702X"],["dc.title","Risk of progression in macula-on rhegmatogenous retinal detachment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]